Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, February 11 2021 - 20:05
Acknowledged scientific leader and Novartis veteran joins Sai Life Sciences
HYDERABAD, India, 11 February 2021 /PRNewswire-AsiaNet/ --

    Sai Life Sciences, one of India's fastest growing Contract Research, 
Development & Manufacturing Organizations [] 
(CRDMOs), today announced the addition of Dr. Mahavir Prashad, an acknowledged 
scientific leader and industry veteran, to its scientific leadership team as 
Vice President of Early Phase Process Development. With over three decades of 
experience in advanced research, and roles of increasing responsibility in one 
of the world's leading pharmaceutical companies, Dr. Prashad will provide 
impetus to Sai Life Sciences' growing capabilities and help accelerate the drug 
development programmes of its customers.

    Making the announcement, CEO & Managing Director of Sai Life Sciences, 
Krishna Kanumuri said, "We see Early Phase Process Development as a key pivot 
in compressing the time to market of our clients' drug development programs. 
This priority has now received significant momentum with the joining of Dr. 
Mahavir Prashad. His deep scientific expertise and rich experience of managing 
outsourced drug development programs will no doubt be a valuable addition as we 
strive to build a world class delivery engine."

    Dr. Prashad is a recognized leader in chemical process R&D and leveraging 
green chemistry principles and modern technologies in API synthesis. He 
possesses an excellent scientific track record through 94 publications, 4 
review articles, 1 book chapter, 71 patent/applications, and 10 invited 
lectures at scientific conferences. He was awarded Novartis Leading Scientist 
award in 2002 and also the 2010 Diversity & Inclusion award of the Novartis 
Pharmaceuticals Corporation. Dr. Prashad has a Ph.D. in Organic Chemistry from 
the Central Drug Research Institute in Lucknow, India and was awarded a 
Post-Doctoral Research Fellowship at Duke University in North Carolina, USA.

    Commenting on his appointment, Dr. Mahavir Prashad said, "I am very excited 
to be joining Sai Life Sciences and its passionate leadership team with a clear 
Early Phase Development acceleration strategy. I am looking forward to working 
with talented and dedicated scientists at Sai who are enabling their partners 
in delivering novel medicines to patients in a speedy and socially responsible 
manner through science and innovation."

    Sai Life Sciences is currently amid an organization-wide transformation. It 
is investing US$150 million during 2019-23, as part of the Sai Nxt initiative, 
across three core areas – people & culture, processes & automation, 
infrastructure & scientific capabilities.

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO/ CDMO 
rashad] driven by a vision to support the launch of 25 new medicines by 2025.  
It works with innovator pharma and biotech companies globally, accelerating the 
discovery, development, and manufacture of complex small molecules. As a 
pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development 
programs, consistently delivering value based on its quality and 
responsiveness. Today, it works with 7 of the top 10 large pharma companies, as 
well as several small and mid-sized pharma & biotech companies. Sai Life 
Sciences is privately held and backed by global investors, TPG Capital and HBM 
Healthcare Investments. 


    Source: Sai Life Sciences